West Pharmaceutical Services (WST) to Release Earnings on Thursday

West Pharmaceutical Services (NYSE:WST) is anticipated to announce its Q3 2025 results before the market opens on Thursday, October 23rd. Analysts expect the company to announce earnings of $1.67 per share and revenue of $788.4150 million for the quarter. West Pharmaceutical Services has set its FY 2025 guidance at 6.650-6.850 EPS.Parties are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Thursday, October 23, 2025 at 8:00 AM ET.

West Pharmaceutical Services (NYSE:WST) last announced its quarterly earnings data on Thursday, July 24th. The medical instruments supplier reported $1.84 EPS for the quarter, beating analysts’ consensus estimates of $1.51 by $0.33. The firm had revenue of $766.50 million for the quarter, compared to analyst estimates of $725.11 million. West Pharmaceutical Services had a return on equity of 18.43% and a net margin of 16.48%.The business’s quarterly revenue was up 9.2% compared to the same quarter last year. During the same period last year, the company earned $1.52 EPS. On average, analysts expect West Pharmaceutical Services to post $7 EPS for the current fiscal year and $8 EPS for the next fiscal year.

West Pharmaceutical Services Trading Up 1.5%

WST stock opened at $274.71 on Tuesday. The company has a quick ratio of 2.08, a current ratio of 2.78 and a debt-to-equity ratio of 0.07. West Pharmaceutical Services has a twelve month low of $187.43 and a twelve month high of $352.33. The company has a market cap of $19.75 billion, a P/E ratio of 41.12, a PEG ratio of 4.81 and a beta of 1.07. The business has a fifty day moving average of $255.62 and a 200-day moving average of $232.01.

West Pharmaceutical Services Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, November 19th. Shareholders of record on Wednesday, November 12th will be issued a dividend of $0.22 per share. The ex-dividend date of this dividend is Wednesday, November 12th. This represents a $0.88 annualized dividend and a yield of 0.3%. This is an increase from West Pharmaceutical Services’s previous quarterly dividend of $0.21. West Pharmaceutical Services’s dividend payout ratio (DPR) is presently 12.57%.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the stock. Wall Street Zen raised shares of West Pharmaceutical Services from a “hold” rating to a “buy” rating in a research note on Saturday, July 26th. Redburn Partners set a $311.00 price objective on shares of West Pharmaceutical Services in a research note on Monday, September 15th. Rothschild & Co Redburn started coverage on shares of West Pharmaceutical Services in a report on Monday, September 15th. They set a “buy” rating and a $311.00 target price for the company. Evercore ISI set a $350.00 price target on West Pharmaceutical Services in a research note on Tuesday, October 7th. Finally, Rothschild Redb upgraded West Pharmaceutical Services to a “strong-buy” rating in a research report on Monday, September 15th. Two investment analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $321.89.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. CYBER HORNET ETFs LLC acquired a new position in West Pharmaceutical Services in the second quarter valued at about $25,000. MUFG Securities EMEA plc acquired a new position in shares of West Pharmaceutical Services in the 2nd quarter valued at approximately $47,000. State of Wyoming acquired a new position in shares of West Pharmaceutical Services in the 2nd quarter valued at approximately $49,000. Darwin Wealth Management LLC bought a new stake in West Pharmaceutical Services during the 2nd quarter worth approximately $75,000. Finally, EverSource Wealth Advisors LLC raised its holdings in West Pharmaceutical Services by 78.2% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 449 shares of the medical instruments supplier’s stock worth $98,000 after buying an additional 197 shares during the period. 93.90% of the stock is currently owned by institutional investors.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.